Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study
2023 · Annals of Oncology · 42 citations
https://doi.org/10.1016/j.annonc.2023.04.516